Sunday, March 02, 2025 | 10:37 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Viatris eyes $1 billion revenue from eye care acquisitions by 2028

Company has bought ophthalmology business of Taparia family-backed Famy Life Sciences

Medical college
Premium

The ophthalmology franchise will function as a separate division within the company

Sohini Das Mumbai
Viatris Inc, the US healthcare company formerly known as Mylan Laboratories, aims to add $1 billion by 2028 as global sales after its recent acquisitions in ophthalmology (eye care).

In India, the company acquired the ophthalmology business of Taparia family-backed Famy Life Sciences for $300 million (around Rs 2500 crore). Viatris will develop a handful of under-development products under phase 3 clinical trials.

These products are in the areas of dry eye disease, Blepharitis (inflammation of the eyelids), Presbyopia (gradual loss of eyes' ability to focus on nearby objects), Viatris said in an investor presentation.

Viatris will acquire Oyster Point

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in